Accepted at 7:51 p.m. Oct, 10, 2024 by Stapedius
Author: alexlewis
Related Note: 1684241642856
Rationale for change

Q&A, +tags

Text Text
Extra
Extra (Synced)
Empty field
Personal Notes
Empty field
Missed Questions
Empty field
eTG Complete
Talley & O'Connor
Empty field
Additional Resources
Empty field
Additional Resources (Synced)
Empty field
Source
One by one
Empty field
Changed Tags
#Malleus_CM::#eTG_Complete::Psychotropic::Dementia #Malleus_CM::#Resources_by_Rotation::Internal_Medicine::Geriatric_Medicine #Malleus_CM::#Pharmacology::16_Neurological_drugs::04_Drugs_for_Alzheimer’s_disease::01_Anticholinesterases_in_Alzheimer’s_disease::Donepezil::03_Indications #Malleus_CM::#Pharmacology::16_Neurological_drugs::04_Drugs_for_Alzheimer’s_disease::01_Anticholinesterases_in_Alzheimer’s_disease::Galantamine::03_Indications #Malleus_CM::#Pharmacology::16_Neurological_drugs::04_Drugs_for_Alzheimer’s_disease::01_Anticholinesterases_in_Alzheimer’s_disease::Rivastigmine::03_Indications
#Malleus_CM::#Subjects::Psychiatry::08_Neurocognitive_Disorders::Dementia::10_Management #Malleus_CM::#Yield::High #Malleus_CM::#Resources_by_Rotation::Psychiatry #Malleus_CM::#Resources_by_Rotation::Internal_Medicine::Neurology #Malleus_CM::#Subjects::Neurology_&_Special_Senses::09_Neurodegenerative_Disorders::01_Neurocognitive_Disorders::Alzheimer's_Disease::10_Management